Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter ...

Investing.com -- Moody’s Ratings has uplifted the rating of Royalty Pharma plc’s senior unsecured notes from Baa3 to Baa2. The outlook for the company has also been revised, shifting from positive to ...

Royalty Pharma (NasdaqGS:RPRX) recently affirmed its dividend, setting it at $0.22 per Class A ordinary share for the second quarter of 2025, demonstrating its financial stability and commitment to ...

Shares of Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) have been given a consensus recommendation of “Buy” by the five ratings firms that are covering the company, MarketBeat.com reports.

Royalty Pharma announces $0.22 dividend per share for Q2 2025, payable on June 10 to shareholders of record by May 16. Royalty Pharma plc has announced that its board of directors has approved a ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ...

In its first-quarter 2025 investor letter, Patient Capital Opportunity Equity Strategy highlighted stocks such as Royalty Pharma plc (NASDAQ:RPRX). Royalty Pharma plc (NASDAQ:RPRX) is a buyer of ...

BofA raised the firm’s price target on Royalty Pharma (RPRX) to $42 from $41 and keeps a Buy rating on the shares. The firm, in its preview of Q1 EPS updates for its commercial-stage biopharma ...

Royalty Pharma Stock Down 0.3 % Shares of NASDAQ:RPRX opened at $31.03 on Tuesday. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20. The company’s fifty day moving ...